Evidence map›Paper›PMID 30886816›Full record

ArticlePreventive medicine reports2019

The role of provider characteristics on the hepatitis A and B vaccination status of adults in the United States during 2007-2015.

P K Ghaswalla, B J Patterson, W Y Cheng, E Duchesneau, M Macheca, M S Duh, A F Trofa

Open access · goldAbstract read
In one paragraph

Article in Preventive medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

P K GhaswallaGSK, 5 Crescent Drive, Philadelphia, PA 19112, USA.
B J PattersonGSK, 5 Crescent Drive, Philadelphia, PA 19112, USA.
W Y ChengAnalysis Group, Inc., 111 Huntington Ave. 14th Floor, Boston, MA 02199, USA.
E DuchesneauAnalysis Group, Inc., 111 Huntington Ave. 14th Floor, Boston, MA 02199, USA.
M MachecaAnalysis Group, Inc., 111 Huntington Ave. 14th Floor, Boston, MA 02199, USA.
M S DuhAnalysis Group, Inc., 111 Huntington Ave. 14th Floor, Boston, MA 02199, USA.
A F TrofaGSK, 5 Crescent Drive, Philadelphia, PA 19112, USA.
Analysis Group (United States) · USGlaxoSmithKline (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis A and B vaccine coverage is suboptimal in US adults, even among those at increased risk for infection, morbidity, or mortality. To understand where medical education and resources might enhance vaccine coverage, it is important to first identify providers and places most commonly associated with the administration of hepatitis vaccinations. We conducted a retrospective analysis of commercial and Medicare insurance claims data from 2007 to 2015 to describe provider types and places of vaccination against hepatitis A and B among adults in the US, and estimated the time to initial vaccination from first diagnosis of a condition for which the Advisory Committee on Immunization Practices (ACIP) recommends hepatitis A and/or B vaccination among at-risk adults. We identified 183,326 adults who received hepatitis A vaccine, 148,119 hepatitis B vaccine, and 64,953 a bivalent vaccine. Mean age was 42.1-45.8 years. Family practice and internal medicine physicians were the main vaccine providers: 38.9% and 20.2% for hepatitis A, 43.7% and 21.4% for hepatitis B, 35.3% and 15.9% for bivalent vaccinations, respectively. ≥90% of initial vaccinations occurred in an office practice. In at-risk patients, median time to first-dose received was 11.8, 20.9, and 20.9 months for hepatitis A, hepatitis B, and hepatitis A/B vaccines, respectively. Primary care and office practices were the most common providers and places of vaccination, respectively, for hepatitis A and B vaccine. For at-risk patients, further research is needed to design vaccination strategies to improve the median time from first ACIP-recommended condition diagnosis to initial vaccination against hepatitis A and B.

Indexed as

ACIP, advisory committee on immunization practicesAdultCDC, centers for disease control and preventionCLD, chronic liver diseaseCPT, current procedural terminologyEMR, electronic medical recordHBV, hepatitis B virusHepatitis AHepatitis BICD-9-CM, international classification of disease, ninth revision, clinical modificationUnited StatesVaccination

Identifiers

PMID30886816
PMCPMC6402425
OpenAlexW2916978419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.